| Primary |
| Cytomegalovirus Infection |
24.6% |
| Encephalitis Cytomegalovirus |
18.5% |
| Myelodysplastic Syndrome |
16.9% |
| Cytomegalovirus Viraemia |
12.3% |
| Acute Lymphocytic Leukaemia |
7.7% |
| Graft Versus Host Disease |
4.6% |
| Prophylaxis |
4.6% |
| Prophylaxis Against Graft Versus Host Disease |
4.6% |
| Anal Abscess |
1.5% |
| Antiviral Prophylaxis |
1.5% |
| Pneumonitis |
1.5% |
| Product Used For Unknown Indication |
1.5% |
|
| Encephalitis Cytomegalovirus |
11.1% |
| Oesophagitis Ulcerative |
11.1% |
| Death |
7.4% |
| Penile Ulceration |
7.4% |
| Renal Salt-wasting Syndrome |
7.4% |
| Confusional State |
3.7% |
| Cytomegalovirus Chorioretinitis |
3.7% |
| Cytomegalovirus Infection |
3.7% |
| Dystonia |
3.7% |
| Encephalitis |
3.7% |
| Fungal Sepsis |
3.7% |
| General Physical Health Deterioration |
3.7% |
| Grand Mal Convulsion |
3.7% |
| Hypocalcaemia |
3.7% |
| Immune Reconstitution Syndrome |
3.7% |
| Lethargy |
3.7% |
| Multi-organ Failure |
3.7% |
| Necrosis |
3.7% |
| Nephropathy Toxic |
3.7% |
| Neuropathy Peripheral |
3.7% |
|
| Secondary |
| Cytomegalovirus Infection |
12.3% |
| Drug Use For Unknown Indication |
9.5% |
| Cytomegalovirus Viraemia |
9.0% |
| Hiv Infection |
9.0% |
| Prophylaxis Against Graft Versus Host Disease |
9.0% |
| Encephalitis Cytomegalovirus |
5.6% |
| Prophylaxis Against Transplant Rejection |
5.6% |
| End Stage Aids |
5.1% |
| Graft Versus Host Disease |
4.6% |
| Bone Marrow Conditioning Regimen |
4.4% |
| Idiopathic Thrombocytopenic Purpura |
4.2% |
| Prophylaxis |
3.9% |
| Myelodysplastic Syndrome |
3.5% |
| B-cell Lymphoma Refractory |
2.8% |
| Antiviral Prophylaxis |
2.5% |
| Immunosuppression |
2.5% |
| Genital Herpes |
2.1% |
| B-cell Unclassifiable Lymphoma Low Grade |
1.6% |
| Antiviral Treatment |
1.4% |
| Myeloid Leukaemia |
1.4% |
|
| Viral Mutation Identified |
11.4% |
| Encephalitis |
10.1% |
| Renal Failure |
10.1% |
| Renal Impairment |
8.9% |
| Neutropenia |
7.6% |
| Drug Resistance |
5.1% |
| Nephropathy Toxic |
5.1% |
| Sepsis |
5.1% |
| Tenderness |
5.1% |
| Cytomegalovirus Infection |
3.8% |
| Lethargy |
3.8% |
| Neuropathy Peripheral |
3.8% |
| Grand Mal Convulsion |
2.5% |
| Granulocytopenia |
2.5% |
| Necrosis |
2.5% |
| Pulmonary Toxicity |
2.5% |
| Renal Failure Acute |
2.5% |
| Septic Shock |
2.5% |
| Transfusion-related Acute Lung Injury |
2.5% |
| Vomiting |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
23.5% |
| Product Used For Unknown Indication |
16.2% |
| Prophylaxis Against Graft Versus Host Disease |
7.1% |
| Hiv Infection |
5.6% |
| Antiviral Prophylaxis |
5.4% |
| Antifungal Prophylaxis |
4.3% |
| Prophylaxis |
4.3% |
| Infection |
4.0% |
| Cytomegalovirus Infection |
3.9% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Stem Cell Transplant |
3.6% |
| Acute Myeloid Leukaemia |
3.5% |
| Nausea |
2.5% |
| Prophylaxis Against Transplant Rejection |
1.9% |
| Bone Marrow Conditioning Regimen |
1.8% |
| Graft Versus Host Disease |
1.8% |
| Infection Prophylaxis |
1.8% |
| Pain |
1.8% |
| Vomiting |
1.8% |
| Blood Pressure |
1.7% |
|
| Drug Resistance |
11.6% |
| White Blood Cell Count Decreased |
11.6% |
| Renal Failure |
7.4% |
| Viral Haemorrhagic Cystitis |
6.3% |
| Neutropenia |
5.3% |
| Pneumonia |
5.3% |
| Sepsis |
5.3% |
| Thrombocytopenia |
5.3% |
| Bone Marrow Failure |
4.2% |
| Epilepsy |
4.2% |
| Nephropathy Toxic |
4.2% |
| Thrombotic Microangiopathy |
4.2% |
| Death |
3.2% |
| Drug Ineffective |
3.2% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.2% |
| Graft Versus Host Disease In Intestine |
3.2% |
| Hypokalaemia |
3.2% |
| Leukopenia |
3.2% |
| Multi-organ Failure |
3.2% |
| Viral Mutation Identified |
3.2% |
|
